Abstract

The purpose of this research: to conduct a retrospective analysis of patient data after transarterial chemoembolization of the hepatic artery. Methods. A retrospective study was carried out. In the general structure of oncological patients with liver cancer during the observed period, there were 456 patients, of which 137 underwent courses of transarterial chemoembolization of the hepatic artery, the prevailing majority of which are men - 81 people. The average age of patients in the sample was 64.6±7.82 years. Results. n the group of patients undergoing transarterial chemoembolization of the hepatic artery, in addition to primary liver cancer, there were also metastatic liver lesions - 42 cases, of which cancer of the rextosigmoid junction predominated (26 cases). The average duration of the disease was 19.2±5.2 months, the median was 17.6 months. The most common diseases were arterial hypertension (45 cases) and chronic heart failure (33 cases). 22 patients received targeted therapy, 33 patients received multicomponent chemotherapy, 113 patients received transarterial chemoembolization of the hepatic artery, and 12 patients underwent surgical treatment. Conclusions. According to the results of a retrospective analysis of patient data after transarterial chemoembolization of the hepatic artery, the most common comorbidities were arterial hypertension and chronic heart failure, most patients received doxorubicin and irinotecan more often.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.